AlexanderEPerlMD

PubMed

• 45 citations
  Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia.
  Andrew H Matthews, Alexander E Perl, Selina M Luger, Alison W Loren, Saar I Gill
  Blood Advances. 2022-07-12
• 28 citations
  Advances in patient care through increasingly individualized therapy
  Courtney D. DiNardo, Alexander E. Perl
  Nature Reviews. Clinical Oncology. 2019-02-01
• 248 citations
  Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia
  Christine M. McMahon, Timothy T. Ferng, Jonathan Canaani, Eunice S. Wang, Jennifer J.D. Morrissette
  Cancer Discovery. 2019-08-01

Journal Articles

• Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors  
  Alexander Perl, MD, Clinical Cancer Research
• Phase 2b Study of Two Dosing Regimens of Quizartinib Monotherapy in FLT3-ITD Mutated, Relapsed or Refractory AML  
  Alexander E Perl, Mark J Levis, Stuart L Goldberg, Martin S Tallman, Hagop M Kantarjian, Gary J Schiller, Blood

Abstracts/Posters

• Characterization of Response and Transfusion Independence in Patients with FLT3-Internal Tandem Duplication (FLT3-ITD)_Mutated Relapsed/Refractory Acute Myeloid Leukem...
  Alexander E. Perl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)Clinically Relevant Abstract
  Alexander E. Perl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Clinical Outcomes and Characteristics of Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)...
  Alexander E. Perl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Single Cell Sequencing Reveals Evolution of Tumor Heterogeneity of Acute Myeloid Leukemia on Quizartinib
  Alexander E. Perl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral TrialCl...
  Alexander E. Perl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
  Alexander E. Perl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL
  Alexander E. Perl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Quality-Adjusted Time without Symptoms or Toxicity (Q-TWiST) Analysis of Quizartinib Vs Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) FLT3-ITD Acute ...
  Alexander E. Perl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b StudyClinically Relevant Abstract 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Treating Acute Myeloid Leukemia: Case Challenges and Emerging Therapies 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Longitudinal Monitoring of AML Tumors with High-Throughput Single-Cell DNA Sequencing Reveals Rare Clones Prognostic for Disease Progression and Therapy Response 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Tr... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Phase 2 Study of Actinium-225 (225Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Outcomes of Allogeneic Stem Cell Transplantation for AML and MDS Based on Pre-Transplant MRD Status By Next-Generation Sequencing 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• New Therapies for Better Patient Outcomes in Acute Myeloid Leukemia: Integration of Recent Data Sets Into Clinical Practice 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Join now to see all